

**ondine**



**For Immediate Release**

## **Ondine Announces Findings in Photodisinfection Treatment of MRSA to be Presented at the Society for General Microbiology's 162<sup>nd</sup> Meeting in Scotland**

**Vancouver, Canada – March 6<sup>th</sup> 2008** - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP; the “Company”), a medical technology company developing photodisinfection based products, today announced that results from two research studies from its *Methicillin Resistant Staphylococcus aureus* (MRSA) program will be presented at the Society for General Microbiology's 162<sup>nd</sup> Meeting held March 31 - April 3, 2008 in Edinburgh, Scotland. The studies provide detailed results of Ondine's photodisinfection system in the eradication of *Staphylococcus aureus*, a bacterium which secretes potent cell wall-bound virulence factors that enhance host tissue destruction. *Staphylococcus aureus* has become resistant to many antibiotics including in some cases to vancomycin, often considered the antibiotic of last resort. These studies were conducted under Professor Michael Wilson, Head of Microbiology at UCL's Eastman Dental Institute as part of an ongoing research collaboration between Ondine Biopharma and the University College London (UCL).

“MRSA is known to produce toxins that are responsible for destroying cell tissue. These toxins continue to destroy the tissue even after antibiotics have killed the organism,” stated Professor Michael Wilson. “Ondine's photodisinfection technology kills both the bacteria and substantially inactivates these toxins, something that none of the antibiotics used to kill MRSA today are able to accomplish. This dual-mode approach also does not contribute to bacterial resistance, another critical advantage of Ondine's photodisinfection system.”

“The attention given to this work by the scientific and medical communities is a testament to the high level of interest in developing non-antibiotic treatments to help curb the spread of MRSA,” said Dr. Cale Street, Ondine's Director of Research. “These and other studies using Ondine's technology at UCL are at the leading edge of scientific progress in the field of photodisinfection, and are being translated into therapies for MRSA nasal decolonization and the treatment of wound and other topical infections.”

The following two abstracts are scheduled to be presented:

Presentation Number MI-03:

“Lethal photosensitization of *Staphylococcus aureus* using a tin chlorin e6-gold Nanoparticle.”  
Dekker, L., Gil-Tomas, J., Narband, N., Nair, N., Parkin., Street, C., and Wilson, M.

Presentation Number MI-04:

“Inactivation of staphylococcal virulence factors using light-activated antimicrobial agents.”

Tubby, S., Wilson, M., Street, C., and Nair, S.

Additional information on these presentations and the Society for General Microbiology can be found at <http://www.sgm.ac.uk/default.cfm>.

### **About Ondine Biopharma Corporation**

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados. For additional information, please visit the Company's website at: [www.ondinebiopharma.com](http://www.ondinebiopharma.com).

### **Forward-Looking Statements:**

*Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.*

*The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.*

### **For further information please contact:**

Carolyn Cross  
President and  
Chief Executive Officer  
Ondine Biopharma Corporation  
(604) 669-0555  
[ccross@ondinebiopharma.com](mailto:ccross@ondinebiopharma.com)

Christina Bessant  
Investor Relations  
The Equicom Group Inc.  
(416) 815-0700 ext. 269  
[cbessant@equicomgroup.com](mailto:cbessant@equicomgroup.com)

Irma Gomez-Dib  
Media & Investors Relations  
FD International  
(212) 850-5761  
[Irma.gomez-dib@fd.com](mailto:Irma.gomez-dib@fd.com)

Canaccord Adams Ltd  
Nominated Adviser & Broker  
Neil Johnson /  
Ryan Gaffney  
+4420 7050 6500